Poorly absorbed antibiotics for the treatment of traveler's diarrhea

Clinical Infectious Diseases

Volumn 41, Issue SUPPL. 11, 2005, Pages

  Taylor, David N ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BICOZAMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; LOPERAMIDE; NEOMYCIN; NIFUROXAZIDE; PHTHALYLSULFATHIAZOLE; PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEFECATION DISORDER; DISEASE DURATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; FLATULENCE; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; INTESTINE INFECTION; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TRAVELLER DIARRHEA; VOMITING;

ANTI-BACTERIAL AGENTS; DIARRHEA; HUMANS; TRAVEL;

EID: 28044470494     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432953     Document Type: Conference Paper

References (38)

1. Guerrant RL, Van Gilder T, Stein TS, et al. Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-50.
2. Gorbach SL, Carpenter C, Grayson R, et al. Consensus conference: travelers' diarrhea. JAMA 1985; 253:2700-4.
3. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-7.
4. Steffen R. The emerging role of nonabsorbable oral antibiotic therapy in the management of travelers' diarrhea. Adv Stud Med 2003; 3:S951-8.
5. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34:628-33.
6. DuPont HL. Community-acquired diarrheal disease in western countries: applications of nonabsorbable oral antibiotic therapy. Adv Stud Med 2003; 3:S945-50.
7. Ericsson CD. Travelers' diarrhoea. Int J Antimicrob Agents 2003; 21:116-24.
8. DuPont HL. Treatment of travelers' diarrhea. J Travel Med 2001; 8(Suppl 2):S31-3.
9. Rees JH, Soudain SE, Gregson NA, et al. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333:1374-9.
10. Taylor DN, Connor BA, Shlim DR. Chronic diarrhea in the returned traveler. Med Clin North Am 1999; 83:1033-52.
11. Ilnyckyj A, Balachandra B, Elliott L, et al. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98:596-9.
12. Steffen R, Tornieporth N, Clemens SA, et al. Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med 2004; 11:231-7.
13. Kemmerer TP, Cetron M, Harper L, et al. Health problems of corporate travelers: risk factors and management. J Travel Med 1998; 5:184-7.
14. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99:1774-8.
15. Taylor DN. The growing problem of antimicrobial resistance among enteric pathogens. Clin Updates Infect Dis 2003; 6:1-4. Available at: http://www.nfid.org/publications/clinicalupdates/id/enteric.pdf. Accessed 11 June 2003.
16. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999; 340:1525-32.
17. Molbak K, Baggesen DL, Aarestrup FM, et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999; 341:1420-5.
18. Horiuch S, Inagaki Y, Yamamoto N, et al. Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother 1993; 37:2486-9.
19. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341-5.
20. Isenbarger DW, Hoge CW, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis 2002; 8:175-80.
21. Jain D, Sinha S, Prasad KN, et al. Campylobacter species and drug resistance in a north Indian rural community. Trans R Soc Trop Med Hyg 2005; 99:207-14.
22. Putnam SD, Riddle MS, Wierzba TF, et al. Antimicrobial susceptibility trends among Escherichia coli and Shigella spp. isolated from rural Egyptian paediatric populations with diarrhoea between 1995 and 2000. Clin Microbiol Infect 2004; 10:804-10.
23. Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 2004; 190:1150-7.
24. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
25. Ericsson CD, DuPont HL, Sullivan P, et al. Bicozamycin, a poorly absorbed antibiotic, effectively treats travelers' diarrhea. Ann Int Med 1983; 98:20-5.
26. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073-8.
27. DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-15.
28. DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: an unabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998; 59:708-14.
29. Infante RM, Ericsson CD, Jiang Z-D, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004; 2:135-8.
30. DuPont HL, Ericsson CD, Mathewson JJ, et al. Oral aztreonam, a poorly absorbed, yet effective, therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992; 267:1932-5.
31. Ericsson CD, DuPont HL, Galindo E, et al. Efficacy of bicozamycin in preventing traveler's diarrhea. Gastroenterology 1985; 88:473-7.
32. DuPont HL, Ziang Z-D, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-12.
33. Meuris B. Observational study of travelers' diarrhea. J Travel Med 1995; 2:11-5.
34. Bouree P, Kouchner G, Ponti M. Double-blind study of traveller's diarrhoea using nifuroxazide. Trans R Soc Trop Med Hyg 1987; 81:859.
35. Haltalin KC, Nelson JD, Hinton LV, Kusmiesz HT, Sladoje M. Comparison of orally absorbable and nonabsorbable antibiotics in shigellosis: a double-blind study with ampicillin and neomycin. J Pediatr 1968; 72:708-20.
36. Kean BH, Schaffner W, Brennan RW. The diarrhea of travelers. V. Prophylaxis with phthalylsulfathiazole and neomycin sulphate. JAMA 1962; 180:367-71.
37. DuPont HL, Jian Z-D, Okhuysen PC, et al. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis 2005; 41(Suppl 8):S571-6 (in this supplement).
38. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 2004; 10:1009-11.